1. Home
  2. LGCL vs LUCD Comparison

LGCL vs LUCD Comparison

Compare LGCL & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGCL
  • LUCD
  • Stock Information
  • Founded
  • LGCL 2009
  • LUCD 2018
  • Country
  • LGCL China
  • LUCD United States
  • Employees
  • LGCL N/A
  • LUCD N/A
  • Industry
  • LGCL
  • LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • LGCL
  • LUCD Health Care
  • Exchange
  • LGCL NYSE
  • LUCD Nasdaq
  • Market Cap
  • LGCL 48.3M
  • LUCD 49.0M
  • IPO Year
  • LGCL 2024
  • LUCD 2021
  • Fundamental
  • Price
  • LGCL $0.55
  • LUCD $0.82
  • Analyst Decision
  • LGCL
  • LUCD Strong Buy
  • Analyst Count
  • LGCL 0
  • LUCD 4
  • Target Price
  • LGCL N/A
  • LUCD $3.63
  • AVG Volume (30 Days)
  • LGCL 98.9K
  • LUCD 258.9K
  • Earning Date
  • LGCL 11-22-2024
  • LUCD 11-13-2024
  • Dividend Yield
  • LGCL N/A
  • LUCD N/A
  • EPS Growth
  • LGCL 11.49
  • LUCD N/A
  • EPS
  • LGCL 0.14
  • LUCD N/A
  • Revenue
  • LGCL $173,306,912.00
  • LUCD $4,189,000.00
  • Revenue This Year
  • LGCL N/A
  • LUCD $91.72
  • Revenue Next Year
  • LGCL N/A
  • LUCD $139.38
  • P/E Ratio
  • LGCL $4.15
  • LUCD N/A
  • Revenue Growth
  • LGCL N/A
  • LUCD 179.27
  • 52 Week Low
  • LGCL $0.47
  • LUCD $0.63
  • 52 Week High
  • LGCL $5.00
  • LUCD $1.50
  • Technical
  • Relative Strength Index (RSI)
  • LGCL N/A
  • LUCD 47.55
  • Support Level
  • LGCL N/A
  • LUCD $0.80
  • Resistance Level
  • LGCL N/A
  • LUCD $0.88
  • Average True Range (ATR)
  • LGCL 0.00
  • LUCD 0.05
  • MACD
  • LGCL 0.00
  • LUCD 0.01
  • Stochastic Oscillator
  • LGCL 0.00
  • LUCD 34.65

About LGCL LUCAS GC LIMITED

Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China.

About LUCD Lucid Diagnostics Inc.

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

Share on Social Networks: